Members' Business Motion · S2M-02602 · Session 2
Treatment of Alzheimer's Disease
The motion
That the Parliament notes with concern the preliminary recommendations of the National Institute for Clinical Excellence (NICE) which, while recognising the effectiveness of three dementia drugs, donepezil, rivastigmine and galantamine, to many sufferers, recommends withdrawing these drugs on the grounds of cost to the NHS in England and Wales; endorses the call by Alzheimer Scotland that all patients with Alzheimer’s disease who are considered suitable by their doctors for these treatments should receive them until it can be shown that either they are not or are no longer benefiting, and considers that the Scottish Executive should ensure that the NICE recommendations are not adopted by NHS Scotland to avoid a disastrous decision for the 62,000 sufferers of dementia in Scotland and their families.
Signatures by party
19 MSPs besides the lodger · 19 from other partiesParty on the day each MSP signed. Signing a motion is voluntary and not whipped. Who signs whose motions
Vote
No recorded vote on this motion. Most motions are never debated, and many that are debated are agreed without a division. Vote records are published from 2011.
Supporters
19 MSPsSNP 9 SSP 4 Con 3 Ind 2 LD 1
Show all 19 supporters by party
SNP 9
- Brian Adam
- Rob Gibson
- Christine Grahame
- Adam Ingram
- Tricia Marwick
- Alex Neil
- Stewart Stevenson
- Andrew Welsh
- Sandra White
SSP 4
Con 3
Ind 2
LD 1
Party shown is each supporter’s party when the motion was published.
In the Official Report
No contribution in the Official Report cites S2M-02602 by reference.